Targeted delivery of immune therapy for liver cancer treatment
Transcatheter Intra-Arterial Delivery of Oriented Anti-PD-L1 Immune checkpoint inhibitors Immobilized Nanocarriers for Local Combination Immunotherapy of Hepatocellular Carcinoma
['FUNDING_R01'] · NORTHWESTERN UNIVERSITY AT CHICAGO · NIH-11062425
This study is looking at a new way to treat liver cancer by using tiny carriers to deliver immune therapy right to the tumor, which could make the treatment work better and cause fewer side effects, and patients may have a chance to try this promising approach for better results.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHWESTERN UNIVERSITY AT CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-11062425 on ClinicalTrials.gov |
What this research studies
This research focuses on improving treatment for hepatocellular carcinoma (HCC), a common and deadly liver cancer. It investigates a method to deliver immune checkpoint inhibitors directly to the tumor site using specialized nanocarriers, which may enhance the effectiveness of the therapy while minimizing side effects. By combining this targeted approach with local ablation therapies, the research aims to overcome the challenges of the tumor microenvironment that often limits the success of traditional immunotherapy. Patients may have the opportunity to participate in innovative treatment strategies that could lead to better outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with hepatocellular carcinoma who are not suitable for surgical resection or transplantation.
Not a fit: Patients with early-stage hepatocellular carcinoma who can undergo surgical resection or transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with hepatocellular carcinoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using localized immunotherapy approaches for cancer treatment, indicating that this method may build on successful strategies.
Where this research is happening
CHICAGO, UNITED STATES
- NORTHWESTERN UNIVERSITY AT CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KIM, DONG-HYUN — NORTHWESTERN UNIVERSITY AT CHICAGO
- Study coordinator: KIM, DONG-HYUN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.